- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Bovine desiccated thyroid products known as "natural" thyroid preparations are offered over the counter or by mail and may or may not contain thyroid hormone. One of these medications was the reason why a patient who took it instead of thyroxine experienced inconsistent thyroid test findings.
Additional research revealed that the remedy contained physiologically active thyroid hormone and had the potential to result in hyperthyroidism.
Because the hormonal composition of a natural thyroid product is unclear and because natural thyroid preparations are biologically active but not standardised, using them as a thyroxine substitute runs the risk of either causing hyperthyroidism or a relapse of hypothyroidism.
A prescribed drug known as desiccated thyroid extract (DTE), also referred to as natural desiccated thyroid (NDT) and porcine thyroid, is created from the dried, desiccated thyroid glands of animals.
As a thyroid hormone replacement therapy for hypothyroidism, DTE medications, which go by the brand names Armour Thyroid, Nature-Throid, NP Thyroid, and WP Thyroid, have been around for a while and are still well-liked by homoeopathic, alternative, and integrative doctors. (hypothyroidism).
The Global Natural Desiccated Thyroid DrugsMarket accountedfor $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Humans convert T4 to triiodothyronine when treated with levothyroxine (LT4) for hyperthyroidism. (T3). Thus, LT4 dosages should replenish the body's T3 reserve while also bringing serum thyrotropin (TSH) levels back to normal. Evidence suggests that T3 in patients receiving LT4 is not completely restored.
Clinical recommendations advise LT4+LT3 therapy as a trial for patients who experience symptoms despite receiving LT4 treatment. A suitable starting point is to decrease the dose of LT4 by 25 mcg/day and add 2.5â7.5 mcg of liothyronine (LT3) once or twice per day.
With these doses of LT4 and LT3, transient bouts of hypertriiodothyroninemia are unlikely to rise above the reference range and have not been linked to negative drug reactions.
A prescription drug called desiccated thyroid extract (DTE) is used to address hypothyroidism. The prescription is offered under the name names Armour Thyroid, Nature-Throid, NP Thyroid, and WP Thyroid, and is occasionally referred to as natural desiccated thyroid or porcine thyroid.
Triiodothyronine (T3) and thyroxine (T4), which are produced by your thyroid gland, are combined naturally to create Armour Thyroid (desiccated thyroid). The essential roles that thyroid hormones play include regulating your metabolism, body temperature, heart rate, and other bodily processes.
Taking thyroid replacement hormones like Armour Thyroid (desiccated thyroid) is common when the hormone level is too low.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introdauction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in theIndustry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Admin Pvt Ltd. All rights reserved.